Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A clinical breakdown of rapamycin (sirolimus) compounding regulations, FDA approval history, label indications, and what patients need to know about legally obtaining compounded sirolimus for off-label use.
Read clinical reviewA physician-reviewed analysis of sirolimus FAERS adverse event reports, FDA label warnings, post-market surveillance findings, and what the data means for off-label longevity use.
Read clinical reviewA detailed review of every major FDA label change to rapamycin (sirolimus) between 2020 and 2026, including new safety warnings, dosing revisions, and post-market surveillance findings.
Read clinical reviewA comprehensive clinical and regulatory guide to sirolimus (rapamycin): FDA approval history, patent litigation, current label requirements, and post-market safety data, reviewed by the HealthRX medical team.
Read clinical reviewA clinical review of sirolimus regulatory history, current off-label longevity research, next-generation rapalogs in development, and what the FDA pipeline means for patients in 2026.
Read clinical reviewA detailed comparison of how the FDA and EMA regulate sirolimus (Rapamune), covering approved indications, black box warnings, post-market surveillance, and the off-label longevity debate.
Read clinical review